Andere Sprachen Allogene Therapeutics, Inc.

Aktien

A2N6WN

US0197701065

ALLO

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 22.05.2024			% 5 Tage	% 1. Jan.
2,66 ^USD	-1,12 %		-10,74 %	-17,13 %

21.05.	ALLOGENE THERAPEUTICS, INC. : Bewertung von Oppenheimer zum Kaufen erhalten	ZM
16.05.	ALLOGENE THERAPEUTICS, INC. : HC Wainwright gibt eine Kauf-Bewertung ab	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Allogene Therapeutics Prices $110 Million Offering	13.05.
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock	13.05.
Allogene Therapeutics: Q1 Earnings Snapshot	13.05.
Allogene Therapeutics Q1 Loss Narrows, Revenue Declines	13.05.
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update	13.05.
Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update	06.05.
Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development	26.04.
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma	26.04.
Allogene Therapeutics Receives Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma	26.04.
Allogene Therapeutics Announces Q2 Investor Conference Participation	09.04.
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index	18.03.
Allogene Therapeutics Files $500 Million Mixed Shelf	15.03.
Allogene Therapeutics Q4 Loss Narrows, Revenue Drops	14.03.
Allogene Therapeutics: Q4 Earnings Snapshot	14.03.
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update	14.03.
Allogene Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	14.03.
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease	12.03.
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update	05.03.
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference	28.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Allogene Therapeutics, Inc.

Aktien

A2N6WN

US0197701065

ALLO

Andere Sprachen

Filter